Ruxolitinib's Role in Treating Polycythemia Vera
OncLive That was defined on the study based on eligibility for phlebotomy. The study showed that it met the primary endpoint, the composite one. It showed better control or a higher rate of complete hematological responses. That's the benefit. Regarding ... |
from phlebotomy - Google News http://bit.ly/2M3HdE2
No comments:
Post a Comment